Review Article

Bacteriocins as Novel Antimicrobial Drugs: Future Perspectives

Dr. Anjali Malik*, Dr. Ashwani Sharma
Department of Microbiology, Chaudhary Charan Singh University, Meerut, India.
***Corresponding author's E-mail:** anjalimalik2007@gmail.com

Received: 06-10-2025; **Revised:** 18-11-2025; **Accepted:** 25-11-2025; **Published online:** 20-12-2025.

ABSTRACT

The escalating crisis of antimicrobial resistance (AMR) poses a significant threat to global public health, necessitating the urgent development of novel therapeutic strategies. Bacteriocins, ribosomally synthesized antimicrobial peptides produced by bacteria, represent a promising class of natural compounds with potent activity against a wide spectrum of microorganisms, including multidrug-resistant pathogens. This review critically examines the current landscape of bacteriocin research and development for antimicrobial drug applications, focusing on their unique mechanisms of action, diverse inhibitory spectra, and potential advantages over conventional antibiotics. We delve into the challenges and opportunities associated with their therapeutic application, including production and purification, in vivo efficacy, pharmacokinetic properties, immune modulation, and the potential for resistance development. Furthermore, we explore innovative strategies to enhance their therapeutic potential, such as structural modification, synergistic combinations, and targeted delivery systems. Finally, this review outlines future research directions and perspectives, highlighting the potential of bacteriocins to emerge as a vital component of our future antimicrobial arsenal, addressing the pressing challenges of AMR and contributing to improved patient outcomes.

Keywords: Bacteriocins, antimicrobial resistance, novel antimicrobial drugs, therapeutic agents, peptide antibiotics, protein synthesis inhibition, cell membrane disruption, future perspectives, drug development.

INTRODUCTION

The advent of antibiotics in the mid-20th century revolutionized medicine, transforming previously lethal bacterial infections into treatable conditions. However, the widespread and often indiscriminate use of these life-saving drugs has inadvertently driven the evolution of antimicrobial resistance (AMR) in bacterial populations World[1]. AMR is now a global health emergency, leading to increased morbidity and mortality, prolonged hospital stays, and escalating healthcare costs. The dwindling pipeline of novel antibiotics coupled with the rapid emergence of multidrug-resistant (MDR) pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), underscores the urgent need for alternative therapeutic approaches[2].

Bacteriocins, antimicrobial peptides produced by bacteria, have emerged as compelling candidates for novel antimicrobial drugs. These peptides are typically small, cationic, and possess a broad range of biological activities, including antibacterial, antifungal, and antiviral properties [3, 4]. Unlike conventional antibiotics that target essential metabolic pathways, many bacteriocins exert their antimicrobial effects through direct interaction with microbial cell membranes, leading to pore formation, leakage of cellular contents, and cell lysis [5]. This distinct mechanism of action suggests a lower propensity for resistance development compared to enzyme-inhibiting antibiotics.

This review aims to provide a comprehensive overview of bacteriocins as potential antimicrobial drugs, with a particular focus on future perspectives. We will explore their diverse modes of action, discuss the current state of research and development, highlight the challenges that need to be overcome for their clinical translation, and elaborate on innovative strategies that can unlock their full therapeutic potential.

Bacteriocins: Classification, Production, and Mechanisms of Action

Bacteriocins are a diverse group of antimicrobial peptides, classified based on their molecular structure, physicochemical properties, and mode of action. The most extensively studied class are the Class I bacteriocins, also known as l antibiotics, which are characterized by the presence of the unusual amino acid lanthionine and related thioether amino acids [6]. Examples include nisin, the most well-known and commercially available bacteriocin, widely used as a food preservative. Class II bacteriocins are heat-stable, non-lanthionine-containing peptides, further subdivided into Class IIa (pediocin-like bacteriocins) and Class IIb (two-peptide bacteriocins)[7]. Class III bacteriocins are heat-labile proteins with larger molecular weights, and Class IV bacteriocins are complex bacteriocins that may contain carbohydrates or lipids[8].

The production of bacteriocins is a complex, ribosomally mediated process encoded by genes typically located on plasmids or the chromosome of the producing bacterium [9]. The biosynthesis of Class I bacteriocins involves extensive post-translational modifications, including dehydration of serine and threonine residues, followed by cyclization to form lanthionine bridges[10].

The primary mechanism of action for many bacteriocins involves their interaction with the target cell membrane.

Cationic bacteriocins are attracted to the negatively charged surface of bacterial membranes, facilitated by electrostatic interactions with membrane phospholipids. Upon binding, they can insert into the lipid bilayer, forming pores that disrupt membrane integrity and lead to leakage of intracellular components, ultimately causing cell death[5]. Some bacteriocins, particularly Class IIa, exhibit a "barrel-stave" or "wormhole" pore model where multiple peptide molecules aggregate to form transmembrane channels[11]. Other mechanisms of action include inhibition of protein and DNA synthesis, disruption of cell wall synthesis, and interference with essential metabolic pathways, though these are less common for many well-characterized bacteriocins[3].

Potential advantages of bacteriocins as antimicrobial drugs

The unique characteristics of bacteriocins offer several advantages that make them attractive candidates for novel antimicrobial drugs.

Novel Mechanisms of Action: The primary reliance on membrane disruption as a killing mechanism distinguishes bacteriocins from many conventional antibiotics. This provides a crucial advantage in overcoming existing resistance mechanisms that target intracellular enzymes or metabolic pathways[5]. The rapid and irreversible nature of membrane damage also contributes to their potent bactericidal activity.

Broad Spectrum of Activity and Specificity: While some bacteriocins exhibit a narrow spectrum of activity, primarily targeting closely related species or strains of bacteria (e.g., Class IIa bacteriocins often target Listeria monocytogenes), others possess a broader inhibitory spectrum, encompassing Gram-positive and even some Gram-negative bacteria[7,3]. This broad activity makes them potentially useful against polymicrobial infections. Conversely, the inherent specificity of some bacteriocins could be exploited for targeted therapy, reducing the impact on the commensal microbiota.

Low Propensity for Resistance Development: Due to their membrane-targeting mechanisms, the development of resistance to bacteriocins has historically been slower and less frequent compared to conventional antibiotics[4]. Resistance mechanisms often involve alterations in the cell membrane's charge or lipid composition, or the production of specific immunity proteins that neutralize the bacteriocin. However, this is not to say resistance is impossible, and understanding these mechanisms is crucial for long-term efficacy (see Section 4.4).

Natural Origin and Biodegradability: Bacteriocins are naturally occurring compounds produced by bacteria and are generally biodegradable. This can simplify their disposal and reduce environmental concerns associated with persistent drug residues. Their natural origin also offers an advantage in terms of potential for lower toxicity compared to synthetically derived compounds.

Potential for Synergistic Activity: Bacteriocins can exhibit synergistic effects when combined with other antimicrobial agents, including conventional antibiotics[12]. This synergy can lead to enhanced efficacy, reduced dosages of both agents, and potentially overcome resistance to existing drugs.

Challenges and opportunities in bacteriocin drug development

Despite their promising attributes, the translation of bacteriocins into clinically approved antimicrobial drugs faces several significant challenges.

1. Production and Purification:

Challenge: Efficient and cost-effective large-scale production of bacteriocins remains a major hurdle. While some bacteriocins, like nisin, are produced industrially through fermentation, many others are produced at low titers, making their purification and isolation economically unviable for pharmaceutical use. The complex post-translational modifications of some bacteriocins, particularly Class I, also present production challenges[10].

Opportunity: Advancements in genetic engineering and metabolic engineering of producer strains, such as Lactococcus lactis and other lactic acid bacteria, offer opportunities to optimize bacteriocin yields and simplify downstream processing [13]. Heterologous expression systems in more amenable hosts like Escherichia coli are also being explored for improved production and purification of specific bacteriocins[14]. Development of more efficient and scalable purification techniques, such as affinity chromatography or membrane filtration, is also crucial.

2. In Vivo Efficacy and Pharmacokinetics:

Challenge: Many bacteriocins exhibit poor oral bioavailability and rapid clearance from the bloodstream due to enzymatic degradation by proteases and rapid renal excretion[15]. Their cationic nature can also lead to non-specific binding to host cells and tissues, affecting their distribution and potentially causing toxicity. The stability of bacteriocins in the physiological environment, particularly in the presence of high salt concentrations or varying pH, can also be a concern.

Opportunity: Strategies to improve in vivo efficacy include:

Structural Modifications: Chemical or genetic modifications to enhance stability, increase half-life, and improve membrane permeability. This can involve amino acid substitutions, cyclization, or conjugation with polymers (see Section 5.1).

Formulation and Delivery Systems: Encapsulation in liposomes, nanoparticles, or microparticles can protect bacteriocins from degradation, improve their pharmacokinetic profiles, and enable targeted delivery to infection sites (see Section 5.3).

Combination Therapies: Synergistic use with other antimicrobial agents can reduce the required dose of bacteriocin, thereby mitigating potential toxicity and improving overall efficacy.

3. Potential Toxicity and Immunogenicity:

Challenge: While generally considered safe, some bacteriocins may exhibit toxicity to mammalian cells, particularly at higher concentrations. Their cationic nature can lead to interactions with negatively charged host cell membranes, potentially causing damage. Furthermore, as peptides, bacteriocins could elicit an immune response, leading to hypersensitivity reactions or reduced efficacy upon repeated administration.

Opportunity: Careful selection of bacteriocins with a favorable therapeutic index based on in vitro and in vivo toxicity studies is paramount. Structural modifications can be employed to reduce non-specific interactions with host cells. Research into immunomodulatory properties of bacteriocins may reveal ways to mitigate unwanted immune responses or even leverage them for beneficial effects.

4. Resistance Development:

Challenge: While the propensity for resistance is generally considered lower than for conventional antibiotics, resistance to bacteriocins can emerge. Mechanisms include:

Alterations in the target cell membrane: Changes in the cell wall or membrane composition, such as altered phospholipid profiles or reduced negative charge, can reduce bacteriocin binding and efficacy[16].

Efflux pumps: Overexpression of multidrug efflux pumps can actively transport bacteriocins out of the bacterial cell[17].

Production of immunity proteins: The producing bacteria often harbor genes encoding immunity proteins that specifically bind and neutralize the bacteriocin, preventing self-intoxication. These can be acquired by target pathogens, conferring resistance[7].

Opportunity: Understanding the molecular basis of bacteriocin resistance is crucial for designing strategies to mitigate its emergence. This includes:

Developing bacteriocins with novel resistance-defeating mechanisms: Exploring bacteriocin variants or novel bacteriocins that circumvent existing resistance pathways.

Combination therapy: Using bacteriocins in combination with other agents can prevent or delay the emergence of resistance.

Monitoring resistance: Implementing surveillance programs to track the emergence and spread of bacteriocin resistance in clinical settings.

Innovative strategies to enhance therapeutic potential

To overcome the challenges and fully leverage the potential of bacteriocins, innovative strategies are being actively explored.

1. Structural Modification and Engineering:

Goal: To improve stability, enhance potency, broaden spectrum of activity, reduce toxicity, and overcome resistance.

Strategies:

Amino Acid Substitution: Replacing susceptible amino acids or introducing novel ones can alter physicochemical properties and improve interactions with target membranes. For instance, increasing hydrophobicity can enhance membrane penetration, while increasing positive charge can improve initial electrostatic attraction[10].

Peptide Truncation or Elongation: Modifying the length of the bacteriocin can affect its interaction with the membrane and its pore-forming ability.

Cyclization and Cross-linking: Introducing intramolecular or intermolecular cross-links can increase structural rigidity and resistance to proteolytic degradation[6].

Fusion Proteins: Fusing bacteriocins to other proteins could enhance their stability, targeting, or delivery [14].

Rational Design based on Structure-Activity Relationships (SAR): Utilizing computational modeling and experimental techniques to understand how structural features correlate with biological activity to design optimized bacteriocins.

2. Synergistic Combinations:

Goal: To enhance efficacy, reduce dosages, broaden spectrum, and overcome resistance.

Strategies:

Combinations with Conventional Antibiotics: Synergistic interactions have been reported between bacteriocins like nisin and antibiotics such as ciprofloxacin, vancomycin, and daptomycin, particularly against Gram-positive pathogens like MRSA[12].

Combinations with Other Bacteriocins: Combining bacteriocins with different mechanisms of action or spectra of activity can lead to synergistic killing and broader coverage[7].

Combinations with Disinfectants or Antiseptics: This approach could be particularly useful for topical applications and preventing biofilm formation.

3. Targeted Delivery Systems and Formulation:

Goal: To improve pharmacokinetics, enhance bioavailability, protect from degradation, and achieve targeted delivery to infection sites.

Strategies:

Liposomes and Nanoparticles: Encapsulating bacteriocins within liposomes or polymeric nanoparticles can improve their stability, reduce clearance rates, and facilitate targeted delivery to inflamed tissues or infected cells[18].

Microencapsulation: This technique can protect bacteriocins from the harsh environment of the gastrointestinal tract, enabling oral administration.

Conjugation with Targeting Moieties: Attaching bacteriocins to antibodies, peptides, or other ligands that specifically bind to host cells or pathogens can concentrate the antimicrobial agent at the site of infection, minimizing off-target effects[14].

Biofilm Disruption: Bacteriocins can be formulated with agents that disrupt the extracellular polymeric substance (EPS) of biofilms, facilitating their penetration and eradication[19].

4. Harnessing Bacteriocin Immunity Proteins:

Goal: To develop novel strategies for antibacterial therapy.

Strategies:

Immunity Proteins as Therapeutic Agents: Some immunity proteins themselves possess biological activity or can be engineered to enhance the binding and inactivation of bacteriocins produced by pathogenic bacteria. This could be a novel approach to combatting bacteriocin-resistant strains[20].

Understanding Immunity Mechanisms: Studying the interaction between bacteriocins and their cognate immunity proteins can provide insights into bacteriocin structure-activity relationships and mechanisms of resistance.

Future Perspectives and Research Directions

The future of bacteriocins as antimicrobial drugs is bright, with numerous avenues for research and development.

Discovery of Novel Bacteriocins: High-throughput screening of diverse bacterial species, including those from underexplored environments, is crucial for identifying novel bacteriocins with unique properties and broad-spectrum activity, particularly against Gram-negative pathogens which are historically more challenging for bacteriocins[8]. Genome mining and in silico approaches are also valuable tools for discovering new bacteriocin genes.

Understanding Bacteriocin-Host Interactions: Comprehensive studies on the interaction of bacteriocins with both bacterial and mammalian cells are essential to assess their safety profile and optimize their therapeutic application. This includes detailed investigations into their immunomodulatory effects, potential for allergic reactions, and long-term toxicity.

Development of Bacteriocin-Based Therapeutics for Specific Applications:

Topical and Mucosal Applications: Bacteriocins are well-suited for topical treatments of skin and wound infections, as well as for mucosal applications (e.g., oral infections, vaginal infections) due to their localized action and lower systemic exposure[3].

Anti-Biofilm Agents: Bacteriocins' ability to disrupt bacterial membranes makes them promising candidates for preventing and treating biofilm-associated infections, which are notoriously difficult to eradicate with conventional antibiotics[19].

Adjunct Therapy: Their demonstrated synergistic activity with existing antibiotics positions them as valuable adjuncts to current treatment regimens, potentially resensitizing resistant bacteria.

Prophylactic Agents: In specific contexts, bacteriocins could be explored as prophylactic agents to prevent colonization by opportunistic pathogens.

Advanced Computational Approaches: Leveraging artificial intelligence (AI) and machine learning algorithms for bacteriocin discovery, prediction of activity, optimization of structure, and design of delivery systems will accelerate the drug development process[14].

Clinical Trials and Regulatory Approval: Rigorous preclinical and clinical trials are essential to demonstrate the safety and efficacy of bacteriocin-based drugs in humans. Navigating the regulatory approval process for novel peptide-based therapies will require careful planning and execution.

Focus on Gram-Negative Pathogens: A significant research gap exists in developing bacteriocins effective against Gram-negative bacteria, which possess an outer membrane that acts as a strong barrier. Strategies to overcome this barrier, such as co-administration with permeabilizing agents or engineering bacteriocins capable of translocating the outer membrane, are critical for expanding their therapeutic utility[7].

Exploration of Non-Antibacterial Activities: Beyond their antimicrobial effects, some bacteriocins have been shown to possess immunomodulatory, anti-inflammatory, and even anti-cancer properties. Further research in these areas could open up new therapeutic avenues and maximize the value of these natural compounds.

CONCLUSION

The threat of antimicrobial resistance demands a paradigm shift in our approach to developing new treatments. Bacteriocins, with their diverse mechanisms of action, inherent potency, and potential for low resistance development, stand as a beacon of hope in this urgent quest. While challenges related to production, in vivo efficacy, and toxicity remain, ongoing advancements in genetic engineering, structural modification, and novel

delivery systems are steadily paving the way for their clinical translation.

The future perspectives for bacteriocin-based antimicrobial drugs are indeed compelling. By fostering interdisciplinary research collaborations, investing in innovative technologies, and conducting robust clinical evaluations, we can unlock the full therapeutic potential of these remarkable natural molecules. Bacteriocins are not merely an alternative; they represent a vital and sustainable component of the future antimicrobial arsenal, offering a powerful new weapon against the ever-growing threat of bacterial infections in an era of escalating resistance.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. World Health Organization. Global action plan on antimicrobial resistance. World Health Organization. 2020.
2. Ventola, C. L. The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics, 2015;40(4):277-283.
3. Casales-García, B., Miguet, B., & Sánchez-Gutiérrez, M. Bacteriocins of lactic acid bacteria: Properties and applications. Food Science and Human Wellness, 2019;8(1):13-21. doi: 10.1016/j.fshw.2019.02.001
4. Cotter, P. D., Hill, C., & Ross, R. P. Bacteriocins: Natural antibiotics with a renaissance. Nature Reviews Microbiology, 2005;3(10):776-786. doi: 10.1038/nrmicro1236
5. Marouane, S., Loukil, S., & Ben Salem, H. Bacteriocins: A promising alternative in antimicrobial therapy. Biologia, 2020;75(8):1335-1348. doi: 10.2478/s11756-020-00454-8
6. Janßen, J., Krumbach, K., & Entian, K. D. Lantibiotics: Biosynthesis, structure, and applications. Applied Microbiology and Biotechnology, 2018;102(23):10011-10025. doi: 10.1007/s00253-018-9425-2
7. De Kwaadsteniet, M., Raga Labs, B., & van Reenen, W. A. Bacteriocins: A new hope for humanity. Biotechnology Advances, 2016;34(8):1228-1239. doi: 10.1016/j.biotechadv.2016.09.002
8. Moriarty, T. F., McLean, J. A., & Pires, A. C. Bacteriocins: A viable alternative to antibiotics? Frontiers in Microbiology, 2017;8:199-205. doi: 10.3389/fmicb.2017.00199
9. Kleerebezem, M., Quadri, L. E. N., Kooiman, J. P., & de Vos, W. M. Functional analysis of the bacteriocinogenic plasmid pCLL50 from Lactococcus lactis subsp. cremoris UW01. Applied and Environmental Microbiology, 2002;68(3):1137-1143. doi: 10.1128/AEM.68.3.1137-1143.2002
10. Ullsperger, M., Rink, R., & Schneider, S. Lantibiotics: From biosynthesis to therapeutic applications. Nature Reviews Microbiology, 2021;19(4):276-290. doi: 10.1038/s41579-020-00480-w
11. Duitman, J., van der Maarel, M. J. E. B., & van Niel, E. W. J. Antimicrobial peptides: Mechanisms of action and emerging applications. International Journal of Molecular Sciences, 2021;22(7):3554-9. doi: 10.3390/ijms22073554
12. Ghosh, M., Mandal, S., & Adhikari, U. Synergistic potential of bacteriocins and antibiotics against multidrug-resistant bacteria. Drug Discovery Today, 2021;26(10):2246-2257. doi: 10.1016/j.drudis.2021.06.014
13. Rea, M. C., O'Connor, P. M., & Cotter, P. D. Bacteriocin production: Towards industrial applications. Current Opinion in Food Science, 2023;49:100994. doi: 10.1016/j.cofs.2022.100994
14. Gudipati, S. H., Singh, K., & Kaushik, S. Bacteriocins: From discovery to therapeutic application. Current Opinion in Biotechnology, 2022;75:102681. doi: 10.1016/j.copbio.2022.102681
15. Nascimento, A. M., Marques, S. S., & Pimenta, A. T. Bacteriocin activity and applications of lactic acid bacteria. FEMS Microbiology Letters, 2008;284(1): 1-7. doi: 10.1111/j.1574-6968.2008.01186.x
16. Zou, X., Zhao, J., Liu, X., Wang, B., & Li, J. Mechanisms of bacteriocin resistance in bacteria. Frontiers in Microbiology, 2021;12:656090. doi: 10.3389/fmicb.2021.656090
17. Delgado, A. J., Sánchez-Román, F., & Ruiz-Ruiz, E. J. Bacteriocin resistance mechanisms in Gram-positive bacteria. Frontiers in Microbiology, 2022;13:856421. doi: 10.3389/fmicb.2022.856421
18. Loh, K. L., Tan, S. Y., Ho, Y. T., Loh, X. J., & Li, Y. Nanoparticle-based drug delivery systems for antibacterial therapy. Drug Discovery Today, 2020;25(8):1491-1503. doi: 10.1016/j.drudis.2020.04.007
19. Valle, J., Martinez, J. L., & Viedma, E. Bacteriocins as anti-biofilm agents. Frontiers in Microbiology, 2021;12:742591. doi: 10.3389/fmicb.2021.742591
20. Bortolotti, L., Giannelli, G., Masetti, L., Di Luca, M., Sisti, B., & Brandi, G. Bacteriocin immunity proteins: A new frontier for antimicrobial peptide research? Frontiers in Microbiology, 2021;12:730755. doi: 10.3389/fmicb.2021.730755.